poisar

Stock

Exagen Inc. XGN

$7.66+0.79%

Overview

XGN market data

Price History

XGN price chart · 1M
O
7.55
H
7.75
L
7.42
C
7.66
Vol
12,248.00
Source
US equities market feed
Observed
Aug 26, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$7.55
Previous Close
$7.60
Day High
$7.75
Day Low
$7.42
52 Week High
$7.97
52 Week Low
$2.59
7 Day Return
+3.23%
30 Day Return
+74.49%
90 Day Return
+50.34%
1 Year Return
+132.83%
Daily Notional Volume
$93.8K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$0.93
Diluted earnings per share over the trailing twelve months.
Beta
2.16
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-26.6%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$2.59 – $12.23
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $159.2M · P/B 7.78 · P/S 2.24.

Company News

8 captured
TD Cowen Maintains Buy on Exagen, Raises Price Target to $10Benzinga · Aug 5, 2026, 7:36 PM
B. Riley Securities Reiterates Buy on Exagen, Raises Price Target to $12Benzinga · Aug 5, 2026, 4:50 PM
BTIG Maintains Buy on Exagen, Raises Price Target to $9Benzinga · Aug 5, 2026, 12:08 PM
Exagen shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY2026 sales guidance above estimates.Benzinga · Aug 4, 2026, 2:21 PM
8-K filing — EXAGEN INC. (XGN)SEC EDGAR · Aug 4, 2026, 12:02 PM
Exagen Raises FY2026 Sales Guidance from $70.000M-$73.000M to $72.000M-$75.000M vs $71.560M EstBenzinga · Aug 4, 2026, 12:01 PM
Exagen Q2 EPS $(0.13) Beats $(0.19) Estimate, Sales $19.941M Beat $17.817M EstimateBenzinga · Aug 4, 2026, 12:01 PM
Exagen Announces Publication Of New Systematic Review Demonstrating That AVISE Lupus Algorithm Delivers Superior Diagnostic Accuracy And Consistency Across Patient Populations Compared With Conventional Serologic Tests AloneBenzinga · Jun 1, 2026, 1:03 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock